Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin AntigenPRNewsWire • 07/25/22
HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA DermatologyPRNewsWire • 07/20/22
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of PsoriasisPRNewsWire • 06/28/22
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus VaccinePRNewsWire • 06/23/22
Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and PsoriasisNewsfile Corp • 06/07/22
Key Binding Characteristics of Dusquetide to Important Intracellular Protein IdentifiedPRNewsWire • 06/01/22
Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine PlatformPRNewsWire • 05/23/22
Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial ResultsPRNewsWire • 05/13/22
Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron VariantsBenzinga • 03/17/22
Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and OmicronPRNewsWire • 03/17/22
Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal StudiesPRNewsWire • 01/04/22
Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial ResultsPRNewsWire • 11/12/21
Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United KingdomPRNewsWire • 11/08/21
Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® VaccinePRNewsWire • 11/04/21